Small molecule · Antagonist of endothelin type A receptor (EDNRA) · developed by Novartis
Atrasentan is an endothelin receptor antagonist that binds the endothelin type A receptor with high selectivity over the endothelin type B receptor. It is studied in IgA nephropathy, a kidney disease in which endothelin-1 is thought to contribute to pathogenesis through the endothelin type A receptor.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 12, 2026). Read the full label for the exact wording, limitations and safety information.
Berger DiseaseBergers DiseaseIgA NephropathyImmunoglobulin A NephropathyNephritis IgA Type, Nephropathy IgA TypePrimary IgAN
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →